These findings lend support to the hypothesis that the increase in SHBG levels induced by liraglutide might contribute per se to reduce the risk of developing the metabolic syndrome in PCOS, also considering the effect of SHBG in directly suppressing inflammation and lipid accumulation in macrophages and adipocytes [65]. Here, SHBG is linked to metabolic syndrome.